Read More: Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs ...

Although they are in the same drug class, they are quite different. They are approved by the Food and Drug Administration (FDA) for different indications in various age groups, dosage forms, and ...

The FDA approved Zepbound (tirzepatide ... “This is the first drug treatment for obstructive sleep apnea, and so that’s exciting, and it provides a good opportunity to help the care of ...

To choose the right weight loss treatment solution, you should try to align your goals with a program that best fits your ...

But hCG is not approved for weight loss and there’s no evidence it helps. The U.S. FDA warns against its use, saying that very restrictive diets, such as the hCG diet, are dangerous. The history ...

Retatrutide — an experimental drug nicknamed “triple G” — could be your best shot at a slimmer ... the US Food and Drug Administration (FDA) has approved for weight loss and nine it ...

The Andhra Pradesh cabinet approves two engineering projects worth Rs 2,723 crore for Amaravati, including a green ammonia manufacturing facility and South India's first integrated energy project.

The Food and Drug Administration (FDA) gave the green light ... in combination with a reduced-calorie diet and increased physical activity. “Today’s approval marks the first drug treatment ...

After delay, Roche's Tecentriq Hybreza wins first FDA approval for a subcutaneous PD-L1 drug Opdivo Qvantig’s average administration time of less than five minutes was observed in the Checkmate ...

The Cabinet approved a special package for companies manufacturing DAP fertiliser. This initiative includes financial assistance in addition to the existing subsidies for DAP producers. “ ...

The drug has been specifically approved for adults with moderate-to-severe obstructive sleep apnea and obesity. Its use is recommended alongside increased exercise and a lower-calorie diet.

The FDA’s Center for Drug Evaluation and Research (CDER) approved 50 new small molecules, biologics and oligonucleotide therapeutics last year. The class of 2024 was a little smaller than that ...